				<i></i>					
				Docket Number (Optional) 4943-103 US	Application Number 10/796,936				
	INF	ORM	IATION DISCLOSURE CITATION	Applicant(s)	10//90,230				
			(Use several sheets if necessary)	BOURASSA et al. Filing Date	Group Art Unit				
				March 10, 2004	TBD				
•EX.	AMINER		OTHER DOCUMENTS (Including Author, Til	itle, Date, Pertinent Pages, Etc.)					
19	E JC)	<del>\</del>	The Consensus TrialStudyGroup. "Effects of Ena	lapril on Mortality in Severe Conge	estive Heart Failure." N Engl J. Med.				
1987; 310: 1429-1435.									
-W-									
104		<b>3</b>	The SOLVD Investigators. "Effect of Englapril of Patients With Reduced Left Ventricular Ejection	n Mortality and the Development of Fractions" N Engl J. Med. 1992: 37	f Heart Failure in Asymptomatic 27: 685-691.				
Sept.									
	IND	<del></del>	DA DOLL Wilson DA Armstrong PW et a	"Commonstive Effects of Low Do					
			Packer M, Poole-Wilson PA, Armstrong PW, et al Converting Enzyme Inhibitor Lisinopril on Morbi Circulation. 1999; 23: 2312-2318.	idity and Mortality in Chronic Hea	rt Failure." ATLAS study group.				
			Shindler DM, Kostis JB, Yusuf S, et al., "Diabetes Ventricular Dysfunction (SOLVD) Trials and Regi	Mellitus, A Predictor of Morbidity istry." Am J Cardiol. 1996; 77: 10	and Mortality in the Studies of Left 17-1020.				
	<u> </u>	-	Bourassa MG, Gurne O, Bangdiwala SI, et al. "No	otural History and Patterns of Cur	rent Proctice in Heart Failure." J Am				
			Coll Cardiol. 1993; 22(suppl A): 14A-19A.	Ituiai Itistoi y and a account of the	Cit I I dence us around a will				
<u> </u>	<del> </del>	-	The SOLVD Investigators. "Effect of Englapril o	n Survival in Patients With Reduce	ed Left Ventricular Ejection Fractions				
			and Congestive Heart Failure." N Engl J Med. 19	91; 325: 293-302.					
			Lewis E.J. Hunsicker L.G., Bain R.P., et al. "The Eff N Engl J Med. 1993; 329: 1456-1462.	ect of Angiotensin Converting-enzy	me Inhibition on Diabetic Nephropathy."				
			The ACE Inhibitors in Diabetic Nephropathy Tria Microalbuminuria Receive Angiotensin-Convertin Intern Med. 2001; 134: 370-379.	alist Group. "Should All Patients V ng Enzyme Inhibitor? A meta-ana	Vith Type 1 Diabetes Mellitus and lysis of individual patient data. Ann				
			Parving HH, Larsen M, Hommel E, et al., "Effect Fluorescein in Hypertensive Type-1 Diabetic Patie	of Antihypertensive Treatment on 1 ints with Background Retinopathy.	Blood-Retinal Barrier Permeability to ", Diabetologia 1989; 32: 440-444.				
			The Heart Outcomes Prevention Evaluation Study Ramipril, on Cardiovascular Events in High Risk	/ Investigators. "Effects of an Angle Patients." N Engl J Med. 2000; 342	otensin-Converting-Enzyme-Inhibitor, 2: 145-153.				
<del></del>	ļ	<del>                                     </del>	Yusuf S, Gerstein H, Hoogwerf B, et al., "Ramipr	il and the Development of Diabetes	," JAMA. 2001; 286: 1882-1485.				
ł									
1	<del> </del>	-	The SOLVD Investigators. "Studies of Left Vent	ricular Dysfunction (SOLVD): Ra	tionale. Design and Methods: Two Trial				
	SG		The SOLVD Investigators. "Studies of Left Vent That Evaluate the Effect of Enalapril in Patients	with Reduced Ejection Fraction."	Am J Cardiol. 1990;66:315-322.				
EXAN	MINER	1	/Shirley Gembeh/	DATE CONSIDERED	03/06/2007				
			If citation considered, whether or not citation is in conform the copy of this form with next communication to applicant.		ie through citation if not in conformance and				

P098/REV04

		<u></u>									
			Docket Number (Optional) 4943-103 US	Application Number 10/796,936							
INF		ATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) BOURASSA et al.								
		•	Filing Date	Group Art Unit							
			March 10, 2004	TBD							
*EXAMINER		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
SG	7070 2004	American Diabetes Association. "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus." Diabetes Care. 1997; 20:1183-201.									
DE JUL O T		Gress TW, Nieto FJ, Shahar E, et al., "Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus." N Engl J Med. 2000; 342:905-912.									
TRA	DEM										
Jacob S, Rett K, Wicklmayr M, et al. "Differential Effect of Chronic Treatment With Two Beta-Blocking Agents on Sensitivity: The Carvedilol-Metoprolol Study." J Hypertens. 1996; 14:489-494.											
		Hansson L, Lindholm LH, Niskanen L, et al. "Effe Conventional Therapy on Cardiovascular Morbidi (CAPPP) Randomised Trial." Lancet. 1999;353:61	ty and Mortality in Hypertension: Th	e Inhibition Compared With ne Captopril Prevention Project							
		Lindholm LH, Ibsen H, Borch-Johnsen K, et al. "F Reduction in Hypertension Study." J Hypertens. 2	Risk of New-Onset Diabetes in the Los 2002;20:1879-1886.	sartan Intervention for Endpoint							
		Paolisso G, DeRiu S, Marrazzo G, et al., "Insulin Failure." Metabolism. 1991;40:972-977.	Resistance in Hyperinsulinemia in Pat	ients With Chronic Congestive Heart							
	Disease." Am J Clin Pathol.										
		Uehara M, Kishikawa H, Isami S, et al. "Effect on Without a Sulphydryl Group: Bradykinin May In 1994;37:300-307.	Insulin Sensitivity of Angiotensin Co nprove Insulin Resistance in Dogs and	nverting Enzyme Inhibitors with or I Humans." Diabetologia.							
		Yang HY, Erdos EG, Levin Y. "A Dipeptidyl Card Biochim Biophys Acta. 1970; 214:374-376.	oxypeptidase That Converts Angioter	nsin I and Inactivates Bradykinin."							
		Tomiyama H, Kushiro T, Abeta H, et al., "Kinins with Angiotensin Converting Enzyme Inhibitor."	Contribute to the Improvement of Ins Hypertension. 1994;23:450-455.	ulin Sensitivity During Treatment							
		Leighton B, Budohoski L, Lozeman FJ, et al., "The Effect of Prostaglandins E1, E2 and F2a and Indomethacin on the Sensitivity of Glycolysis and Glycogen Synthesis to Insulin in Stipped Soleus Muscles of the Rat." Biochem J. 1985;27:337-340.									
sg		Fryer LGD, Hajduch E, Rencurel F, et al., "Active Stimulation of Nitric Oxide Synthase." Diabetes. 2	ation of Glucose Transport by AMP-4 000;49:1978-1985.	Activated Protein Kinase via							
EXAMINER		/Shirley Gembeh/	DATE CONSIDERED	03/06/2007							
		citation considered, whether or not citation is in conformation of this form with next communication to applicant.	ance with MPEP Section 609; Draw line th	hrough citation if not in conformance and							

•			Docket Number (Optional)	Application Number						
INF	ORMA	ATION DISCLOSURE CITATION	4943-103 US Applicant(s)	10/796,936						
		(Use several sheets if necessary)	BOURASSA et al.  Filing Date Group Art Unit							
			March 10, 2004	Group Art Unit TBD						
*EXAMINER		OTHER DOCUMENTS (Including Author, Titl	Title, Date, Pertinent Pages, Etc.)							
VAE.	ė,	Henriksen EJ, Jacob S, Kinnick TR, et al., "ACE In Bradykinin and Nitric Oxide." Am J Physiol. 1999;	nhibition and Glucose Transport in In 277:R332-R336.	sulin-Resistant Muscle: Roles of						
, _ en	(C)(0)	<b>2.125, 12.11.</b>								
JUN 0 7 20	3	- Hard -								
SG	ABL S	Balon TW, Nadler JL. "Evidence That Nitric Oxide Increases Glucose Transport in Skeletal Muscle." J Appl Physiol. 1997;82:359-363.								
SG	ARE									
		Shultz TZ, Lewis SB, Westbie DK, et al., "Glucose Muscle." Am J Physiol. 1977;2:E514-E518.	Delivery: A Modulator of Glucose Up	take in Contracting Skeletal						
SG										
		Morel Y, Gadient A, Keller U, et al., "Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol." J Cardiovascular Pharmacol. 1995;26:306-311.								
SG		or Atenolol." J Cardiovascular Pharmacol. 1995;26	:306-311.							
	ļ	D.H. T. Vishall VI. Pares C. HA Companion of the	ha Efforts of Undersklausthianida an	Contouril on Chasse and Linid						
SG		Pollare T, Lithell H, Berne C., "A Comparison of the Metabolism in Patients with Hypertension." N Eng	ne Effects of Hydrochiorothiazide and I J Med. 1989:321:868-873.	Captoprii on Glucose and Lipid						
		Carlsson PO, Berne C, Jansson L. "Angiotensin II Secretion in Rats." Diabetologia. 1998;41:127-133.	and the Endocrine Pancreas: Effects	on Islet Blood Flow and Insulin						
SG		Ç .								
•										
		·								
,										
			•							
	<del> </del>									
CYAMINED	L		DATE CONSIDERED							
EXAMINER		/Shirley Gembeh/	DATE CONSIDERED	03/06/2007						
		citation considered, whether or not citation is in conforma copy of this form with next communication to applicant.	Ince with MPEP Section 609; Draw line th	rough citation if not in conformance and						

- • •					Docket Number (Optional) Application Number						
	INFO	RMATION DISCLOSURE	MOLEGIE	4943-103 US 10/796,936 Applicant(s)			90,930				
·	•	RMATION DISCLOSURE (Use several sheets) Decessar	W 75:	Bourassa, et al.							
		AUS 2	0 2004 ES	Filing Date March 10, 2004		roup Art Unit 1	1614				
U.S. PATENT DOCUMENTS											
•EXAMINER	REF	DOCUMENT NUMBER	ADEMAY	NAME	CLASS	SUBCLASS	FILING	DATE			
INITIAL	REF	DOCUMENT NUMBER	UATE		NAME		3030233	IF APPRO	PRIATE		
				•							
			-								
	<u> </u>										
						- :-	1	<u>-</u>			
	<u> </u>		IIC DATER	ADDITO	TION PUBLICATIONS						
•EXAMINER	Γ	<u> </u>	U.S. PATENI	APPLICA	TION PUBLICATIONS		T - 1				
INITIAL	REF	DOCUMENT NUMBER	DATE		NAME .	CLASS	SUBCLASS	FILING DATE  IF APPROPRIATE			
	·		FORE	GN PATE	NT DOCUMENTS						
	REF	DOCUMENT NUMBER		COUNTRY	CLASS	SUBCLASS	Trans YES	lation NO			
SG		WO 01/15673 A2	03/08/2001	WIPO				123	NO		
SG		WO 03/032963 A2	04/24/2003	WIPO							
						! 					
ļ					7577						
	ļ						<u> </u>				
			OTHER D	OCUMEN	TS (Including Author,	Title, Date, P	ertinent Pages, Et	(c.)	1		
. <del>s</del> €	3	Emmanuelle Vermes, et Circulation; 107 (9): 129	al.: Enalapril Ro	educes the	Incidence of Diabetes in P	a <del>tients With</del>	Chronic Heart	Failure: 2	حند00		
	$\perp$	1 Duplicate									
SG		L. Ryden, et al.; Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus; European Heart Journal; 2000; Vol. 21; 1967-1978									
EXAMINE	ER	/Shirley Gembeh/			DATE CONSIDERED	03/0	5/2007				
EVAMINED. Initial If stacking appellanted substance and clocking in in appearance with MOED Cooking (00). Dogovilland the absolute in the stacking in the stac											
	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

							196,936				
INFORMATION DISCLOSURE CITATION (Use several Oncests if necessary)						Applicant(s) Bourassa, et al.					
AUG 1 5 2005						Filing Date Group Art Unit					
( 3)						March 10, 2004 1614					
U.S. PATENT						DOCUMENTS		<b>.</b>			
*EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME CL		CLASS SUBCLASS		FILING DATE	
EVITIAL		-			······································			<b>†</b>	. IF APPRO	PRIATE	
		<u> </u>				·		<u> </u>			
										•	
								<u> </u>			
		-	<del></del>					1			
				•							
		<u>.                                    </u>		U.S. PATENT	APPLICA	TION PUBLICATIONS		<u> </u>			
•EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING		
LUITAL	<u> </u>	-		<u>                                       </u>					IF APPRO	PRIATE	
•		_						<u> </u>			
									I		
		1							-, -		
		-						<del> </del>			
	ł										
	<del>,</del>		·	FOREI	GN PATE	NT DOCUMENTS					
	REF		DOCUMENT NUMBER	DATE	•	COUNTRY	CLASS	SUBCLASS	Trans YES	lation NO	
		-									
		<u> </u>		<u> </u>							
····		+-						<b>†</b>	-		
					-			<del> </del>			
				OTHER D	OCUMEN	TS (Including Author,	Title, Date, P	ertinent Pages, E	(c.)		
			Emmanuelle Vermes, et	al.; Enalapril Re	duces the	Incidence of Diabetes in P	atients With	Chronic Heart	Failure; 2	003;	
SG			Emmanuelle Vermes, et al.; Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure; 2003; Circulation; 2003; 107: 1285-1290								
	ĺ										
EXAMINE	R	_	/Shirley Gembe	eh/		DATE CONSIDERED	<u>-</u>	03/0	06/2007		
EYAMINE	D. 1-1	rial if a			conformer	lee with MPEP Section 609; D	raw line thro	ugh citation if no	t in conform	ance and	
			copy of this form with next			Dection 007, D	tui V	-0	JVIIIVI III		